New Risk • May 22
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • May 15
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩22,350, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 114% over the past three years. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩21,750, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 106% over the past three years. Reported Earnings • Mar 25
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: ₩1,869 (up from ₩1,355 in FY 2024). Revenue: ₩742.2b (up 24% from FY 2024). Net income: ₩55.9b (up 42% from FY 2024). Profit margin: 7.5% (up from 6.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Revenue is forecast to grow 7.6% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Announcement • Mar 07
Dongsung FineTec Co., Ltd., Annual General Meeting, Mar 26, 2026 Dongsung FineTec Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 120, hyeopdongdanji-gil, miyang-myeon, gyeonggi-do, anseong South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩25,050, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 145% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩37,835 per share. Buy Or Sell Opportunity • Feb 26
Now 21% undervalued Over the last 90 days, the stock has risen 18% to ₩29,200. The fair value is estimated to be ₩37,120, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 51%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 33% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩28,750, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 181% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩37,078 per share. Upcoming Dividend • Dec 22
Upcoming dividend of ₩350 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 22 April 2026. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.3%). Price Target Changed • Dec 06
Price target increased by 7.1% to ₩37,750 Up from ₩35,250, the current price target is an average from 4 analysts. New target price is 51% above last closing price of ₩25,000. Stock is up 87% over the past year. The company is forecast to post earnings per share of ₩1,979 for next year compared to ₩1,355 last year. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩26,500, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 146% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩26,042 per share. Reported Earnings • Nov 20
Third quarter 2025 earnings released: EPS: ₩684 (vs ₩300 in 3Q 2024) Third quarter 2025 results: EPS: ₩684 (up from ₩300 in 3Q 2024). Revenue: ₩201.1b (up 47% from 3Q 2024). Net income: ₩20.5b (up 135% from 3Q 2024). Profit margin: 10% (up from 6.4% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Nov 19
Consensus EPS estimates increase by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩745.7m to ₩761.8m. EPS estimate increased from ₩1,810 to ₩2,064 per share. Net income forecast to grow 34% next year vs 52% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩35,250 to ₩36,000. Share price fell 17% to ₩26,250 over the past week. Board Change • Nov 18
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Declared Dividend • Nov 08
Dividend of ₩350 announced Dividend of ₩350 is the same as last year. Ex-date: 29th December 2025 Payment date: 22nd April 2026 Dividend yield will be 1.1%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (21% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 8.0% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 70% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Nov 07
Dongsung FineTec Co., Ltd. announces Annual dividend, payable on April 22, 2026 Dongsung FineTec Co., Ltd. announced Annual dividend of KRW 350.0000 per share payable on April 22, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. New Risk • Oct 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.4% average weekly change). Price Target Changed • Sep 05
Price target increased by 11% to ₩35,250 Up from ₩31,667, the current price target is an average from 4 analysts. New target price is 9.8% above last closing price of ₩32,100. Stock is up 192% over the past year. The company is forecast to post earnings per share of ₩1,810 for next year compared to ₩1,355 last year. New Risk • Aug 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.0% average weekly change). Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩27,950, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 146% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩37,810 per share. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩25,450, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total returns to shareholders of 130% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩23,826 per share. Buy Or Sell Opportunity • Mar 27
Now 23% undervalued Over the last 90 days, the stock has risen 43% to ₩21,700. The fair value is estimated to be ₩28,332, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 64% in the next 2 years. Price Target Changed • Mar 19
Price target increased by 42% to ₩22,667 Up from ₩15,967, the current price target is an average from 3 analysts. New target price is 6.3% below last closing price of ₩24,200. Stock is up 98% over the past year. The company is forecast to post earnings per share of ₩1,197 for next year compared to ₩993 last year. New Risk • Mar 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Mar 12
Dongsung FineTec Co., Ltd., Annual General Meeting, Mar 27, 2025 Dongsung FineTec Co., Ltd., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 120, hyeopdongdanji-gil, miyang-myeon, gyeonggi-do, anseong South Korea Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩22,950, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total returns to shareholders of 144% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩34,572 per share. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩19,640, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 7x in the Chemicals industry in South Korea. Total returns to shareholders of 112% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩36,678 per share. Upcoming Dividend • Dec 20
Upcoming dividend of ₩250 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 23 April 2025. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (2.2%). New Risk • Dec 08
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩13,480, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total returns to shareholders of 35% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩20,366 per share. Reported Earnings • Aug 17
Second quarter 2024 earnings released: EPS: ₩113 (vs ₩277 in 2Q 2023) Second quarter 2024 results: EPS: ₩113 (down from ₩277 in 2Q 2023). Revenue: ₩137.8b (down 4.3% from 2Q 2023). Net income: ₩3.27b (down 59% from 2Q 2023). Profit margin: 2.4% (down from 5.6% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩11,670, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total returns to shareholders of 5.7% over the past three years. Major Estimate Revision • Jan 26
Consensus EPS estimates increase by 18% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from ₩829 to ₩976. Revenue forecast steady at ₩538.4m. Net income forecast to grow 43% next year vs 73% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩16,667 unchanged from last update. Share price was steady at ₩11,630 over the past week. Upcoming Dividend • Dec 20
Upcoming dividend of ₩350 per share at 2.9% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 18 April 2024. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.8%). Price Target Changed • Nov 17
Price target increased by 11% to ₩16,633 Up from ₩14,950, the current price target is an average from 3 analysts. New target price is 39% above last closing price of ₩11,930. Stock is up 2.8% over the past year. The company is forecast to post earnings per share of ₩829 for next year compared to ₩295 last year. Reported Earnings • Apr 04
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: ₩295 (down from ₩961 in FY 2021). Revenue: ₩434.2b (up 19% from FY 2021). Net income: ₩8.42b (down 68% from FY 2021). Profit margin: 1.9% (down from 7.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 42%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Price Target Changed • Mar 02
Price target decreased by 11% to ₩14,950 Down from ₩16,800, the current price target is an average from 2 analysts. New target price is 39% above last closing price of ₩10,730. Stock is down 2.9% over the past year. The company is forecast to post earnings per share of ₩532 for next year compared to ₩961 last year. Buying Opportunity • Dec 29
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be ₩13,735, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 2.6%. Revenue is forecast to grow by 22% in 2 years. Earnings is forecast to grow by 205% in the next 2 years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩350 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. Payout ratio is on the higher end at 87% but the company is not cash flow positive. Trailing yield: 3.3%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (2.4%). Buying Opportunity • Dec 12
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 9.2%. The fair value is estimated to be ₩13,648, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 2.6%. Revenue is forecast to grow by 22% in 2 years. Earnings is forecast to grow by 205% in the next 2 years. Price Target Changed • Nov 16
Price target increased to ₩20,600 Up from ₩15,667, the current price target is provided by 1 analyst. New target price is 72% above last closing price of ₩11,950. Stock is up 6.7% over the past year. The company is forecast to post earnings per share of ₩695 for next year compared to ₩961 last year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improved over the past week After last week's 15% share price gain to ₩13,700, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 93% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,068 per share. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improved over the past week After last week's 15% share price gain to ₩12,150, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩18,360 per share. Upcoming Dividend • Dec 22
Upcoming dividend of ₩350 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 22 April 2022. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 3.1%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (1.5%). Price Target Changed • Nov 26
Price target decreased to ₩14,500 Down from ₩15,667, the current price target is an average from 4 analysts. New target price is 37% above last closing price of ₩10,550. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩887 for next year compared to ₩808 last year. Price Target Changed • May 19
Price target increased to ₩14,750 Up from ₩13,500, the current price target is provided by 1 analyst. New target price is 12% above last closing price of ₩13,150. Stock is up 58% over the past year. Reported Earnings • Mar 21
Full year 2020 earnings released: EPS ₩808 (vs ₩634 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: ₩388.0b (up 53% from FY 2019). Net income: ₩21.3b (up 26% from FY 2019). Profit margin: 5.5% (down from 6.7% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 05
New 90-day high: ₩12,400 The company is up 19% from its price of ₩10,450 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 26% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩14,130 per share. Price Target Changed • Dec 22
Price target raised to ₩13,750 Up from ₩12,650, the current price target is an average from 3 analysts. The new target price is 19% above the current share price of ₩11,550. As of last close, the stock is up 15% over the past year. Is New 90 Day High Low • Nov 09
New 90-day high: ₩10,900 The company is up 10.0% from its price of ₩9,950 on 11 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩9,528 per share. 
